Articles By Anuja Singh
What Lessons from Sanofi’s 2025 Execution Signal Its Future in Oncology, Immunology, and Vaccines?
Sanofi concluded 2025 with a combination of solid portfolio performance, strategic execution, and continued innovation across its pharmaceuticals,…
ByHow Did Roche’s 2025 Deals Shape Its Strategy and Future Outlook?
In 2025, Roche executed a series of focused deals and collaborations designed to strengthen its scientific platforms, expand…
How Did Roche Navigate 2025 and What Lies Ahead for 2026?
Roche concluded 2025 as a company demonstrating resilient performance, strategic focus, and continued innovation across its pharmaceuticals and…
How Did Johnson & Johnson’s 2025 Deals Shape Its Strategy, and What Do They…
New Brunswick, NJ — In 2025, Johnson & Johnson executed a series of strategic collaborations, acquisitions, and partnerships…
How Did Johnson & Johnson Navigate 2025 and What Lies Ahead for 2026?
Johnson & Johnson concluded 2025 with a combination of resilient portfolio performance, strategic execution, and ongoing innovation across…
How Did Novartis’ 2025 Deals Shape Its Strategic Direction and What Might They Signal…
Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific platforms, broaden its…
What Lessons from Sanofi’s 2025 Execution Signal Its Future in Oncology, Immunology, and Vaccines?
Sanofi concluded 2025 with a combination of solid portfolio performance, strategic execution, and continued innovation across its pharmaceuticals,…
How Did Roche’s 2025 Deals Shape Its Strategy and Future Outlook?
In 2025, Roche executed a series of focused deals and collaborations designed to strengthen its scientific platforms, expand…
How Did Roche Navigate 2025 and What Lies Ahead for 2026?
Roche concluded 2025 as a company demonstrating resilient performance, strategic focus, and continued innovation across its pharmaceuticals and…
How Did Johnson & Johnson’s 2025 Deals Shape Its Strategy, and What Do They…
New Brunswick, NJ — In 2025, Johnson & Johnson executed a series of strategic collaborations, acquisitions, and partnerships…
How Did Johnson & Johnson Navigate 2025 and What Lies Ahead for 2026?
Johnson & Johnson concluded 2025 with a combination of resilient portfolio performance, strategic execution, and ongoing innovation across…
How Did Novartis’ 2025 Deals Shape Its Strategic Direction and What Might They Signal…
Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific platforms, broaden its…